Stocks in play: BriaCell Therapeutics Corp.
Announced U.S. FDA authorization of an Expanded Access Policy (EAP) for metastatic breast cancer (MBC) patients. BriaCell Therapeutics Corp. shares T.BCT are trading up $0.05 at $0.70.
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.